Purpose: Multiparametric magnetic resonance imaging (mpMRI) is an emerging technique aiming to improve upon the diagnostic sensitivity of prostate biopsy. Because of variance in interpretation and application of techniques, results may vary. There is likely a learning curve to establish consistent reporting of mpMRI. This study aims to review current literature supporting the diagnostic utility of mpMRI when compared with radical prostatectomy (RP) and template transperineal biopsy (TTPB) specimens. Methods: MEDLINE and PubMed database searches were conducted identifying relevant literature related to comparison of mpMRI with RP or TTPB histology. Results: Data suggest that compared with RP and TTPB specimens, the sensitivity of mpMRI for prostate cancer (PCa) detection is 80e90% and the specificity for suspicious lesions is between 50% and 90%. Conclusions: mpMRI has an increasing role for PCa diagnosis, staging, and directing management toward improving patient outcomes. Its sensitivity and specificity when compared with RP and TTPB specimens are less than what some expect, possibly reflecting a learning curve for the technique of mpMRI.
Introduction
Prostate cancer (PCa) is the second most common cause of cancer death in Australian men and is the most commonly diagnosed internal malignancy with one in seven Australian men being diagnosed with PCa by the age of 75. 1 PCa may first present with elevated prostate-specific antigen (PSA) on screening or symptomatically with lower urinary tract symptoms, bony pain from metastases or uncommonly with hematuria, urinary retention, or renal failure. 2 The definitive diagnosis of PCa is generally made by a biopsy, typically transrectal ultrasound (TRUS)-guided biopsy.
Staging is typically by a nuclear medicine bone scan or computed tomographyepositron emission tomography. trends in the zonal origin of PCa, particularly the predominance of malignancy within the peripheral zone (PZ) and hence its amenability to detection on digital rectal examination (DRE) and TRUSguided biopsy. However, a minority of cancers arose from more anterior regions of the prostate leading to a newly articulated phenomenon "prostatic evasive anterior tumor syndrome (PEATS)." PEATS describes a subset of PCa which, due to anatomical location, may be missed by traditional investigations such as DRE and TRUS biopsy, both of which primarily focus on the PZ, but may be detected by multiparametric magnetic resonance imaging (mpMRI) or transperineal biopsy (TPB). 5 Management of PCa depends on risk stratification, most commonly the Gleason score, TNM staging, and PSA level. Lower risk cancers may be indolent and require active surveillance (AS) involving (with local variation) monitoring PSA levels (serial PSA tests), DREs, biopsy, and possibly mpMRI or watchful waiting for patients deemed not suitable for active treatment with curative intent by their treating clinician. Higher risk cancers may be treated with radical prostatectomy (RP), external beam or interstitial (brachytherapy) radiotherapy, androgen deprivation therapy, or a combination of these. Newer focal therapies are under investigation. 3 This literature review aims to describe mpMRI and to explore the evolving role for PCa diagnosis and staging. 6 The sensitivity and specificity of mpMRI reported in the literature is approximately 80e90% and 50e90%, respectively, when compared with RP and template TPB (TTPB) specimens.
Materials and methods
MEDLINE and PubMed database searches were conducted from August 2014 to January 2015 using combinations of the MeSH terms "prostate," "prostatic neoplasia," "diagnosis," "magnetic resonance imaging," and using specific search terms such as "mpMRI," "multiparametric," or "erMRI."
Discussion
Multiparametric MRI (mpMRI) is an emerging technique that aims to improve upon the diagnostic sensitivity of prostate biopsy, and ultimately reduce the number of biopsies performed and better direct management decisions. The recently released 2014 National Institute for Health and Care Excellence (NICE) guidelines for management of PCa in the United Kingdom recommended an increasing role for mpMRI based on clinical and cost effectiveness. However, these guidelines recommended against utilizing mpMRI before biopsy due to insufficient cost benefit. 3 It is important to distinguish multiphasic MRI from conventional 1.5-T MRI techniques without dynamic contrast-enhanced MRI (DCE-MRI) or diffusion-weighted imaging (DWI), which have been shown not to be provide sufficiently reliable information for clinical decision making. 7 The sequences involved in mpMRI are detailed in Table 1 . Tables 2 and 3 summarize the literature regarding the diagnostic utility of mpMRI for PCa.
MRI after a negative TRUS
The NICE guidelines recommended consideration of an MRI after negative TRUS biopsy to assess the requirement for an additional biopsy. 3 This particularly relates to PEATS, because anterior or apical tumors may be missed by TRUS biopsy but still be visible on mpMRI. 
Preoperative staging
The NICE guidelines recommended mpMRI to investigate for regional nodal disease and the extent of the primary tumor in men with histologically proven PCa if the tumor growth affects management, such as in preoperative staging. 3 Organ-confined disease enables an operative approach to spare the neurovascular bundle, minimizing concerns regarding positive surgical margins, and thereby reducing postoperative morbidity relating to erectile dysfunction without increasing mortality risk. 13 mpMRI has been Magnetic resonance spectroscopy Magnetic resonance spectroscopy detects increasing (choline þ creatinine)/citrate ratios, which have been correlated with Gleason score.
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A large clinical trial suggested that magnetic resonance spectroscopy provides little additional information compared with T2WI. 23 Magnetic resonance spectroscopy may not be included in mpMRI sequences 16, 24 and is optional in the PIRADS scoring system.
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T1WI
Detects postbiopsy hemorrhage, which confounds other sequences.
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T2WI
Delineates the zonal anatomy of the prostate and capsule, and helps elucidate extracapsular extension. 15 Suspicious characteristics include homogenous areas of low signal with ill-defined margins. 15, 26 Note. From "The role of magnetic resonance imaging in the diagnosis and management of prostate cancer," by J. Thompson ADC, apparent diffusion coefficient; DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; PCa, prostate cancer; PIRADS, Prostate imaging and reporting data system; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; TZ, transition zone. ADC, apparent diffusion coefficient; CL, core length; DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; ERC, endorectal coil; GS, Gleason score; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; NR, not recorded; PCa, prostate cancer; PI-RADS, prostate imaging-reporting and data system; RP, radical prostatectomy; TZ, transition zone; UCL, University College London. 
mpMRI sequences
A 2014 European Consensus Panel and the European Society for Urogenital Radiology (ESUR) agreed that multiphasic MRI should involve various submodalities such as T1-weighted images (T1WIs), T2-weighted images (T2WIs), DWI and DCE as different sequences provide an additive benefit to accuracy. 17, 18 The role of MR spectroscopy is less clear. 18 The 2014 NICE guidelines only recommend obtaining T2WI and DWI images and provide no recommendations regarding field strength or the use of an endorectal coil (ERC). 
Magnetic field strength and ERCs
3-T MRI may be preferred due to increased spatial resolution and signal-to-noise ratio. 17, 18 However, this may not improve diagnostic accuracy. 19, 20 ERC, compared with a pelvic-phased array (PPA), may be used to locally increase spatial resolution while also causing significant patient discomfort. 7 Improvements in diagnostic accuracy are less clear. 20 A 2014 International Consensus Panel recommended the use of ERC at 1.5 T, but considered 3 T as optional; by contrast, the ESUR considers them entirely optional.
17,18
Scoring system for image interpretation
In 2012, the ESUR published a structured reporting system known as the PI-RADS and recommendations on standardizing the mpMRI protocol. 17 The aim of these guidelines was to improve the diagnostic accuracy of mpMRI for PCa, to improve communication between radiologists, and to standardize the literature for better comparisons between studies. A PI-RADS score has components from different MRI sequences and an overall score from one to five, with higher numbers reflecting an increasing probability of PCa risk and aggression. 17 Prior to these publications, many studies used more subjective Likert scales, which have subsequently shown to have greater interobserver variability. 21 Some authors describe the PI-RADS system as a work in progress due to ongoing controversy surrounding MRI protocols and the definition and treatment of clinically significant PCa.
22e24 PI-RADS 3 is considered "equivocal" and it is unclear whether this should be considered positive or not; in particular, the morbidity due to overtreatment of PCa is a concern. The trend is that if equivocal results are included, sensitivity is higher while specificity is lower. Some authors report both and the difference in quantitative results is substantial. For example, Abd-Alazeez et al 25 reported, for University College London (UCL) definition 2, sensitivities of 94% and 68% with specificities of 23% and 69% for PI-RADS of 3 or more and 4 or more, respectively. Typically, it is local practice in Melbourne, Australia, for a radiologist to recommend a biopsy of a PI-RADS 3 lesion. Fig. 1 illustrates the correlation between a PI-RADS 5 lesion identified on mpMRI and an RP specimen.
Reference standard controversy
There is an ongoing controversy surrounding the reference standard to which mpMRI is compared. 26 Various authors advocate comparing MRI with transrectal biopsy, TPB, or whole-mounted prostatectomy specimens. Transrectal biopsies miss 20e30% of clinically significant tumors, typically caused by undersampling of the apex, transition zone (TZ), and anterior horns of the PZ. 2 Template-guided TPB provides a more comprehensive sample.
27
RP whole-mount specimens minimize any sampling error, but exacerbate selection error because men with low-risk disease, who are unfit for surgery, who choose alternative treatments, or those without PCa are not sampled. 26 By focusing on men with high-risk PCa, this approach limits the investigation of the NPV and the role for MRI to reduce unnecessary biopsies. 19 Thompson et al 19 used TTPB and RP and reported similar results.
Benign disease mimicking carcinoma
Benign disease such as benign prostatic hyperplasia, biopsy changes, fibrosis, prostatitis, and prostatic intraepithelial neoplasia can mimic the appearance of cancer on mpMRI. 20 However, Junker et al 23 demonstrated that such mimics are almost exclusively mistaken low-grade carcinoma as indicated by a PI-RADS score of 3 or less.
Timing of MRI postbiopsy
A 2014 European Consensus recommended that mpMRI should be conducted at least 8 weeks after the biopsy to minimize the confounding effect of postbiopsy hemorrhage. 18 Hemorrhage can cause decreased T2 signal potentially masking or mimicking tumors and can involve areas quite distant from the needle trajectory. 28 However, a 2012 study by Rosenkrantz et al 28 involving 44 patients showed that lengthy delay might not be necessary, as hemorrhage can reliably be demonstrated on T1WI.
Definition of clinically significant PCa
As mentioned earlier, PCa can range from indolent to lethal. Appropriate risk stratification is critical to guiding management, to both reduce morbidity from overtreatment and mortality from undertreatment. There is considerable variation in the definition of "clinically significant" PCa. 9 Gleason score of over 4 þ 3 and/or maximum cancer core length (CCL max ) of 6 mm or more; UCL 2: Gleason score of 3þ4 or more and/or CCL max of 4 mm or more. 25, 31, 32 More exclusive definitions of clinically significant PCa tend toward higher sensitivities compared with more inclusive definitions, with small decreases in specificities.
Arumainayagam et al 31 and Abd-Alazeez et al 25, 32 compared the more exclusive UCL 1 with the more inclusive UCL 2, and showed that sensitivity increases by 4e16% and specificity decreases by 0e3%. Thompson et al 19 analyzed four definitions and reported smaller differences of 0e3% for both sensitivity and specificity.
Blinding
The studies in Tables 2 and 3 all used some form of blinding, but the details varied. One would expect that a stricter blinding protocol results in less diagnostic accuracy, but this is not evident in these tables so the effect is likely small.
Patient population and biopsy indication
By definition, sensitivity and specificity are independent of disease prevalence, whereas PPV and NPV are not. Despite this, the differing indications for mpMRI alter the diagnostic accuracy. For example, Grey et al 34 reported sensitivity varying from 85% to 100% across primary biopsy, AS, and previous negative biopsy groups. The effects were more pronounced for NPV varying from 27% to 77%. 33, 34 The two 2014 studies by Abd-Alazeez et al 25, 32 primarily differ in the MRI indication as they are from the same institution over similar periods. In the primary biopsy setting, with significant PCa defined by UCL 2, sensitivity and specificity were reported as 94% and 23%, respectively, compared with 76% and 42% respectively in the repeat biopsy setting. This variation may be accounted for by the systematic differences between the groups in terms of tumor size and location such as PEATS being more common in the previous negative biopsy group. 3.13. Comment on specific papers Tables 2 and 3 summarize the literature regarding the diagnostic utility of mpMRI for PCa. They demonstrate the wide range of results and heterogeneity in terms of patient population, test indication, study design, MRI protocol, scoring system, radiologist experience, biopsy protocol, significant cancer definition, and reference standard, all of which confound direct comparison. Several papers were excluded as they only investigated the MRI sequences individually and not their combined utility. Tables 2 and 3 with some differences as other reference standards such as TRUS biopsy or MRI-guided biopsy were included. The difficulty in imaging the TZ was illustrated by Hoeks et al 40 as they reported disappointing results, with no significant improvement in mpMRI (including both DCE and DWIeMRI) compared with T2WI MRI alone with accuracies of 66% and 68%, respectively. These numbers are comparable to those obtained by a smaller study Yoshizako et al 29 where accuracy decreased from 83% to 79% after DCE was added to T2WI and DWI for TZ PCa. Delongchamps et al 22 again showed the difficulty in imaging the TZ, reporting a maximum sensitivity and specificity of 71% and 98% for the TZ (results not statistically significant), which is less favorable than the PZ with 80% and 97%, respectively. This suggests that PCa location is another confounding factor for comparing studies. Delongchamps et al 22 found that the addition of DCE to an mpMRI protocol reduces accuracy within the TZ and reported sensitivity and specificity of 53% and 83%, respectively, if DCE was included; however, upon excluding DCE, they reported sensitivity and specificity of 71% and 98%, respectively. 22 This was supported by Junker et al 23 who reported a sensitivity and specificity within the TZ as 53% and 83%, respectively, if DCE was included compared with 71% and 98% if DCE was excluded. 23 Junker et al 23 subsequently recommended that the PI-RADS score developed in 2012 by the ESUR be amended to reflect this finding.
Chamie et al 41 demonstrated that the additional benefit of DWI in mpMRI is most significant for higher grade disease, which is particularly relevant as overtreatment of clinically insignificant disease is a concern. Pepe et al 42 also reported that the diameter of lesions identified on mpMRI correlated with aggressiveness. Grey 34 This case suggests that an additional confounding factor is the time from MRI to biopsy and then to RP.
Interobserver variability and a learning curve
Interobserver variability and learning curves are likely contributing factors to the diversity of results in different studies of mpMRI. The effects are greater when Likert scale scoring systems are employed, as they rely heavily on the experience of senior radiologists, and the effects are lessened for more well-defined scoring systems, such as PI-RADS. Gaziev et al 44 demonstrated a significant learning curve for PCa detection with MRI reporting on a Likert scale. The 2-year prospective study reported an increase in cancer detection from 42% to 81%. Vach e et al 21 compared different scoring systems for the diagnosis of PCa on mpMRI. Significant interobserver variability occurred with the subjective Likert scoring system with area under the curve (AUC) scores varying from 0.88 to 0.81. Interobserver variation was minimal across the more rigid scoring systems as PI-RADS AUC varied from 0.75 to 0.76. Pokorny et al, 45 using PI-RADS, demonstrated no significant difference in accuracy between junior and senior radiologists and a urologist after the protocol had been implemented for 18 months. Accuracy did not increase with time across the 6-month study.
Future studies
The UCL Hospital is undertaking the Prostate Imaging Compared to Transperineal Ultrasound Guided Biopsy for Significant Prostate Cancer Risk Evaluation (PICTURE) study and the multicenter PROstate MRI Imaging Study: Evaluation of Multi-parametric Magnetic Imaging in the Diagnosis and Characterisation of Prostate Cancer (PROMIS) designed to prospectively assess the NPV of mpMRI and the role to reduce biopsies. 46 Both studies are expected to be completed in 2014/2015. 47 
MR-guided biopsy
Lawrence et al 48 electronically aligned and fused mpMRI images with three-dimensional real-time TRUS imaging for targeted biopsy. Pokorny et al 45 described in-bore MR-guided prostate biopsy reporting sensitivity and specificity of 92% and 97%, respectively, for intermediate and high-grade PCa. 45 In conclusion, mpMRI has an increasing role for PCa diagnosis, staging, and directing management toward improving patient outcomes. The sensitivity and specificity of mpMRI reported in the literature is approximately 80e90% and 50e90% when compared with RP and TTPB specimens. This is less than what some expect, possibly reflecting a learning curve for the technique of mpMRI.
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